Spring Bank Pharmaceuticals Inc
Spring Bank Pharmaceuticals — Investor Presentation (April 2018)
22 slides from Spring Bank Pharmaceuticals's investor presentation, Apr 25, 2018
Slide 1: Driven by a Novel Pharmaceutical Platform Focused on Selective Immunomodulation
DRIVEN BY A NOVEL PHARMACEUTICAL PLATFORM FOCUSED ON SELECTIVE IMMUNOMODULATION Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements, other than historical facts, regarding: the progress, scope, duration or re
Slide 3: A Company with Innovative Focus
RIG-I Agonists: HBV, HIV latency and other viral infections STING Agonists: immuno-oncology and autoimmune diseases ADDRESSING UNMET NEEDS USING OUR NOVEL SMNH PLATFORM 1 • SPRING BANK PHARMACEUTICALS, INC. © 2018 Clinical-stage biopharmaceutical company engaged in the discovery and development of a
Slide 4: Progressive Pipeline Designed to Meet Significant Unmet Needs
2 • SPRING BANK PHARMACEUTICALS, INC. © 2018 PROGRESSIVE PIPELINE DESIGNED TO MEET SIGNIFICANT UNMET NEEDS SMNH Platform Targets RIG-I STING Agonists Compound Inarigivir (oral): Monotherapy Co-Administration with Gilead’s Viread® Co-Administration with Gilead’s Vemlidy® SB 9225 inarigivir + tenofovi
Slide 5: Chronic HBV: A Global Problem
3 • SPRING BANK PHARMACEUTICALS, INC. © 2018 CHRONIC HBV: A GLOBAL PROBLEM Chronic HBV infection prevalence (approximate) ~257MM GLOBALLY ~17MM US AND EUROPE Estimated Deaths 870,000 (IN 2017) HBV global therapeutics sales $2.4B (IN 2016) LOW TREATMENT RATES OF CHRONIC HBV PATIENTS TODAY Estimated 1
Slide 6: An Opportunity to Change the Chronic HBV Paradigm
4 • SPRING BANK PHARMACEUTICALS, INC. © 2018 AN OPPORTUNITY TO CHANGE THE CHRONIC HBV PARADIGM BY ELEVATING THE FUNCTIONAL CURE RATE A new therapy with: 3 An improved finite course of treatment leading to functional cure rates greater than 8-10%* 2 Ease of administration 1 An excellent safety profil
Slide 7: Inarigivir: A Novel, Oral, Selective Immunomodulator with Dual Mechanism of Action
INARIGIVIR: A NOVEL, ORAL, SELECTIVE IMMUNOMODULATOR WITH A DUAL MECHANISM OF ACTION 5 • SPRING BANK PHARMACEUTICALS, INC. © 2018 Small molecule nucleic acid hybrid (SMNH) Hepatic-selective immunomodulator Favorable safety profile to date Orally bioavailable Physical properties allow for potential f
Slide 8: Inarigivir: Dual Mechanism of Action
6 • SPRING BANK PHARMACEUTICALS, INC. © 2018 INARIGIVIR: A NOVEL, ORAL, SELECTIVE IMMUNOMODULATOR WITH A DUAL MECHANISM OF ACTION HBV, hepatitis B virus; IFN, interferon; pgRNA, pregenomic RNA; P protein, HBV polymerase; RIG-I, retinoic acid-inducible gene-I. Sato et al. Immunity. 2015;42:123-132. R
Slide 9: Inarigivir's Dual Mechanism: Potential Backbone Agent for Combination Cure Strategies
7 • SPRING BANK PHARMACEUTICALS, INC. © 2018 INARIGIVIR’S DUAL MECHANISM OF ACTION: A UNIQUE, POTENTIAL BACKBONE AGENT FOR COMBINATION CURE STRATEGIES Evidence suggests host immune response is necessary for VIRAL CLEARANCE & FUNCTIONAL CURE “Combination of antiviral and immune modulatory therapies w
Slide 10: Clinical Studies of Inarigivir in HBV
8 • SPRING BANK PHARMACEUTICALS, INC. © 2018 CLINICAL STUDIES OF INARIGIVIR IN HBV DNA, deoxyribonucleic acid; HBeAg, hepatitis B e antigen; RNA, ribonucleic acid; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; QD, once daily. PRIMARY ENDPOINT SECONDARY ENDPOINT Safety and antiviral act
Slide 11: Clinical Studies of Inarigivir in HBV: Combination with Viread and Vemlidy
9 • SPRING BANK PHARMACEUTICALS INC. © 2018 CLINICAL STUDIES OF INARIGIVIR IN HBV inarigivir co-administered with Viread® (tenofovir disoproxil fumarate) 300 mg ACHIEVE PHASE II (Part B) Study Viread® monotherapy Inarigivir - 100 mg + Viread® Viread® 12 weeks 12 weeks Viread® monotherapy Anticipated
Slide 12: Anti-Viral Effect at Week 12 After Inarigivir Monotherapy
10 • SPRING BANK PHARMACEUTICALS, INC. © 2018 t-test vs placebo *p<0.03, #p<0.005, $p<0.01, &p<0.01 ANTI-VIRAL EFFECT AT WEEK 12 AFTER INARIGIVIR MONOTHERAPY (25 MG AND 50 MG DAILY) Mean Placebo (n=8) Inarigivir 25 mg HBeAg +ve (n=9) Inarigivir 25 mg HBeAg –ve (n=7) Inarigivir 50 mg HBeAg +ve (n=10)
Slide 13: Anti-Viral Effect at Week 12 Compared to Week After Tenofovir Switch
11 • SPRING BANK PHARMACEUTICALS, INC. © 2018 ANTI-VIRAL EFFECT AT WEEK 24 COMPARED TO WEEK 12 AFTER TENOFOVIR SWITCH Mean Placebo (n=8) Inarigivir 25 mg HBeAg +ve (n=9) Inarigivir 25 mg HBeAg –ve (n=7) Inarigivir 50 mg HBeAg +ve (n=10) Inarigivir 50 mg HBeAg –ve (n=4) Week 12 HBV DNA log10 Change i
Slide 14: Baseline HBV DNA and HBsAg Is a Strong Predictor of Response to Inarigivir
12 • SPRING BANK PHARMACEUTICALS, INC. © 2018 BASELINE HBV DNA AND HBsAg IS A STRONG PREDICTOR OF RESPONSE TO INARIGIVIR At baseline: HBV DNA > 106 HBV DNA < 106 Change in HBV DNA or RNA to week 12 (log10) Baseline HBV DNA <106 is a strong predictor of response to low dose inarigivir Change in HBV D
Slide 15: HBV Heterogeneity and Inarigivir Opportunity
HBeAg - ve 70-80% of chronic HBV patients Dominant population in US & EU Older age group Lower viral burden SB 9225 SB 9225 + siRNA SB 9225 + different MOA or Inarigivir “Stop & Shock” SB 9225 INARIGIVIR OPPORTUNITY HBV HETEROGENEITY Naïve or new to treatment Nuc Suppressed 80,000 patients in US 100
Slide 16: Inarigivir Clinical & Regulatory Plan
INARIGIVIR CLINICAL & REGULATORY PLAN Inarigivir Monotherapy Nuc Suppressed -ve HBeAg HBV Patients “Stop & Shock” POTENTIAL MARKET ENTRY POTENTIAL OPPORTUNITY EXPANSION SB 9225 + siRNA or Differing MOA +ve HBeAg HBV Patients SB 9225 (inarigivir + tenofovir fixed-dose) -ve HBeAg +ve HBeAg HBV Patient
Slide 17: Inarigivir Clinical & Regulatory Plan
SB 9225 + siRNA or other MOA +ve HBeAg “naïve” (highest viral burden) SB 9225 -ve & +ve HBeAg “naïve” INARIGIVIR CLINICAL & REGULATORY PLAN Inarigivir Monotherapy Nuc Suppressed –ve HBeAg 15 • SPRING BANK PHARMACEUTICALS, INC. © 2018
Slide 18: SB 11285: A Novel Synthetic STING Agonist Lead Compound
16 • SPRING BANK PHARMACEUTICALS, INC. © 2018 SB 11285 A NOVEL SYNTHETIC STING AGONIST LEAD COMPOUND A NOVEL SYNTHETIC
Slide 19: SB 11285 – Lead Next Generation STING Agonist
17 • SPRING BANK PHARMACEUTICALS, INC. © 2018 SB 11285 – lead next generation STING agonist Shown to be highly potent & efficacious across multiple cancer models, with associated abscopal and tumor memory responses Multiple routes of administration (IV, IT & SC) Differentiated cyclic dinucleotide /
Slide 20: SB 11285 Significantly Inhibits Tumor Growth in Relevant Oncology Models
18 • SPRING BANK PHARMACEUTICALS, INC. © 2018 SB 11285 SIGNIFICANTLY INHIBITS TUMOR GROWTH IN RELEVANT ONCOLOGY MODELS 4500 4000 3500 3000 2500 2000 1500 1000 500 0 1 4 8 11 15 18 22 Tumor volume (mm3) Days Post Initiation of Treatment A20 Lymphoma (IT) 1600 1400 1200 1000 800 600 400 200 0 1 5 9 12
Slide 21: The Path Forward for Spring Bank: Potential for Multiple Catalysts
19 • SPRING BANK PHARMACEUTICALS, INC. © 2018 2018 2019 THE PATH FORWARD FOR SPRING BANK POTENTIAL FOR MULTIPLE CATALYSTS 1. At 12.31.2017. CMC, chemistry, manufacturing and controls; CTA, clinical trial application; IND, Investigational new drug. 1H 2018 Gilead initiated Phase II study (inarigivir
Slide 22: A Focus on Simplicity, Safety, and Selectivity
20 • SPRING BANK PHARMACEUTICALS, INC. © 2018 SPRING BANK PHARMACEUTICALS, INC. A FOCUS ON SIMPLICITY, SAFETY, AND SELECTIVITY SB 9225 (inarigivir + tenofovir disoproxil fumarate fixed-dosed combination): Advance development in HBV Next-generation STING agonist program: Lead SB 11285 anticipated to
Spring Bank Pharmaceuticals — Investor Presentation (April 2018) on 6ix